US20030032813A1 - Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders - Google Patents
Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Download PDFInfo
- Publication number
- US20030032813A1 US20030032813A1 US10/199,057 US19905702A US2003032813A1 US 20030032813 A1 US20030032813 A1 US 20030032813A1 US 19905702 A US19905702 A US 19905702A US 2003032813 A1 US2003032813 A1 US 2003032813A1
- Authority
- US
- United States
- Prior art keywords
- oxo
- thioxo
- thiazolidin
- signifies
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *.*C1*(=C*C([3*])C2SC(=S)N(C(*)C[Y])C2=O)=C1[W].C Chemical compound *.*C1*(=C*C([3*])C2SC(=S)N(C(*)C[Y])C2=O)=C1[W].C 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Compounds of general formula (I), where m is 0-8, q is 0-8, a is between 0-4, A signifies a single or double bond, R1 and R2 signify hydrogen or lower alkyl, whereby R1 and R2 are the same or different and, when m signifies 2-8, R1 and R2 in the group CR1═CR2 can have various significances, R3 signifies hydrogen or lower alkyl, X signifies hydrogen or —(CH2)b—COR4 with b=0-4, Y signifies hydrogen, —COR4, phenyl or indolyl residue, R4 signifies hydroxyl, lower alkoxy or the NR1R2 residue, whereby R1 and R2 are the same or different, W is optionally mono- or polysubstituted saturated or unsaturated mono-, bi- or tricycle which can contain one or more hetero atoms, as well as physiologically compatible salts, esters, optically active forms, racemates, tautomers, derivatives which can be metabolized in vivo to compounds of general formula (I), and produces medicaments for prophylaxis or therapy of metabolic bone disorders with the compounds.
Description
- The present invention is concerned with rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders, a process for their manufacture as well as medicaments which contain these compounds.
- In healthy persons the synthesis and degradation processes in bones is almost in equilibrium, i.e. the activity of the osteoblasts and osteoclasts is balanced. However, if this equilibrium is disturbed in favour of the osteoclasts ancuor to the detriment of the osteoblasts, this leads to a reduction in the bone mass and to a negative change in the bone structure and function.
- Hitherto, bone resorption inhibitors such as oestrogens, calcitonin and biphosphonates have primarily been used for the treatment of metabolic bone disorders. The use of these substances is, however, limited and also does not show the desired effect in all cases. Compounds which have a stimulating activity on bone synthesis and in addition contribute to an increase in an already reduced bone mass are accordingly of especial significance for the treatment of metabolic bone disorders.
- Compounds having the rhodanine carboxylic acid structural element are known as antidiabetics, cytostatics inflammation inhibitors and for the treatment of cardiovascular illnesses and bacterial infections
- The parathyroid hormone (PTH), a hormone from the parathyroid gland, is the natural ligand of the receptor and an important regulator for the maintenance of the calcium level in the body. PTH can stimulate bone formation or bone resorption. In this, it acts as a regulatory hormone on a series of enzymes, inter alia, on adenylate cydase (cAMP synthesis) and on ornithine decarboxylase. PTH mobilizes calcium from bones in the case of calcium deficiency, reduces calcium excretion from the kidneys and simultaneously improves the resorption of calcium from the intestine by an increased synthesis of 1,25-(OH)2D3. A normalization of the calcium level is achieved by the action on these target organs. On the other hand, the incorporation of calcium in bones is stimulated in the case of an elevated calcium level. This osreoanabolic activity of PTH and its fragments has been attributed to the activation of adenylate cyclase and of cAMP-dependent protein kinases (Rixon, R. Whitfield, J. et al JMBR 9 (8) 1179-89 (1994).
- Surprisingly, it has now been found that rhodanine carboxylic acid derivatives of the present invention stimulate the PTH receptor-mediated cAMP formation. Compounds of the present invention are accordingly suitable for the broad treatment of metabolic bone disorders. They can be used primarily to good effect where the bone synthesis is disturbed, i.e. they are especially suitable for the treatment of osteopenic disorders of the skeletal system such as e.g. osteoporosis, inter alia, osteogenesis imperfecta as well as for the local assistance in bone regeneration and osteoinduction such as e.g. in orthopedic and maxillary medical indications, in fracture healing, osteosyntheses, pseudoarthroses and for the healing in of bone implants. However, having regard to these properties they also find use in the prophylaxis of osteoporosis.
- By their influence on bone metabolism medicaments with the rhodanine carboxylic acid derivatives of the present invention as active substances furthermore form a basis for the local and systemic treatment of rheumatoid arthritis, osteoarthritis and degenerative arthrosis.
-
- in which
- m signifies a number between 0-8,
- q signifies a number between 0-8
- a signifies a number between 0-4
- A signifies a single or double bond
- R1, R2 signify hydrogen or lower alkyl, whereby R1 and R2 can be the same or different and, when m signifies 2-8, R1 and R2 in the group CR1═CR2 can have various significances within the following sequence
- R3 signifies hydrogen or lower alkyl
- X signifies hydrogen or —(CH2)b—COR4 with b=0-4
- Y signifies hydrogen, —COR4, phenyl or indolyl residue
- R4 signifies hydroxyl, lower alkoxy or the NR1R2 residue, whereby R1 and R2 can be the same or different
- W signifies an optionally mono- or polysubstituted saturated or unsaturated mono-, bi- or tricyde which can contain one or more hetero atoms,
- As a rule, lower alkyl signifies linear or branched alkyl residues with one to six carbon atoms, preferably methyl, ethyl, propyl, i-propyl, butyl, t-butyl, pentyl, hexyl, particularly methyl.
- Alkoxy groups signify a combination of a C1-C10-alkyl group in accordance with the above definition with an oxygen atom, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy and pentoxy groups.
- Under monocycle there are to be understood optionally mono- or polysubstituted, saturated or unsaturated ring systems with 3-8, preferably 5-7 carbon atoms, which optionally can be interrupted by one or more hetero atoms, such as nitrogen, oxygen or sulphur, especially the phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, furyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl or 1,2,4-triazolyl residue, as well as residues such as e.g. phenyl phenyl ether, diphenylmetcne and biphenyl. Substituents are preferably lower alkyl alkoxy, alkoxycarbonylalkyl, alkoxycarbonyl, acetylamino, alkoxydialkylamino, amino, dialkylamino, benzyl, benzyloxy, benzyloxybenzyloxy, carboxyl, chiorophenylsulphanyt, dioxymethylene, mercaptoalkyl, nitro, phenoxy, styryl and halogen.
- In the case of the bicycle set forth under W, this is preferably a residue such as the naphthyl, tetrahydronaphthyl, decalinyl, quinolinyl, chromane, chromene, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, indazolyl, oxindolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl or purinyl residue, especially the indolyl, naphthyl, benzimidazolyl, quinolinyl, tetrahydroquinolinyl benzothiophenyl and benzofuranyl residue, which optionally can be mono- or polysubstituted. Substituents are preferably lower alkyl, alkoxy, alkoxycarbonylalkyl, alkoxycarbonyl, acetylamino, alkoxydiakylamino, amino, dialkylamino, benzyl, benzyloxy, benzyloxybenzyloxy, carboxyl, chlorophenylsulphanyl, dioxymethylene, mercaptoalkyl, nitro, phenoxy, styryl and halogen.
- In the case of the tricycle set forth under W, this is preferably a residue such as the anthracene, fluorene, dibenzofuran or carbazole.
- Compounds of formula I wherein W is phenyl or indolyl, m and g are both 0, R3 is hydrogen and A is a double bond are disclosed e.g. in EP-A-0677 and EP-A-0587377, however for the treatment of Alzheimer's disease or as hypoglycemic agents.
-
- in which
- m signifies a number between 0-8,
- q signifies a number between 0-8
- a signifies a number between 0-4
- A signifies a single or double bond
- R1, R2 signify hydrogen or lower alkyl, whereby R1 and R2 can be the same or different and, when m signifies 2-8, R1 and R2 in the group CR1═CR2 can have various significances within the following sequence
- R3 signifies hydrogen or lower alkyl
- X signifies hydrogen or —(CH2)b—COR4 with b=0-4
- Y signifies hydrogen, —COR4, phenyl or indolyl residue
- R4 signifies hydroxyl, lower alkoxy or the NR1R2 residue, whereby R1 and R2 can be the same or different
- W signifies an optionally mono- or polysubstituted saturated or unsaturated mono-, bi- or tricycle which can contain one or more hetero atoms,
- whereas W is not phenyl or indolyl, if m and g are both 0, R3 is hydrogen and A is a double bond, as well as their physiologically compatible salts, esters, optically active forms, racemates, tautomers, as well as derivatives which can be metabolized in vivo to compounds of general formula (I), as well as the use of these compounds for the production of medicaments.
- Preferred are compounds of general formula I in which m signifies a number between 0 and 4, q signifies the number 0 or 1, a signifies a number of 0 to 4, A signifies a double bond, R1,2 signify hydrogen or methyl, X signifies hydrogen or —(CH2)b—COR4 with b=0-2 and R4 equals hydroxyl, methoxy or NR1R2, Y signifies hydrogen or COR4, the phenyl or indolyl residue, R3 signifies hydrogen or methyl and W signifies an optionally mono- or polysubstituted benzothiophene, phenyl, benzofuran, thiophene, naphthalene, piperidine, cyclohexenyl or biphenyl residue.
-
- The rhodanine carboxylic acids and aldehydes used as starting materials are either commercially available, known or can be prepared analogously to the generally known processes.
- Compounds of formula (I) can be administered (sic) in liquid, solid or aerosol form orally, enterally, parenterally, topically, nasally, pulmonary or rectally in all usual non-toxic pharmaceutically acceptable carrier materials, adjuvants and additives. The compounds of formula (I) can also be applied locally to/in the bones (optionally with surgical intervention). The term parenteral embraces subcutaneous, intravenous and intramuscular delivery or infusions. Oral administration forms can be e.g. tablets, capsules, dragees, syrups, solutions, suspensions, emulsions, elixirs etc., which can contain one or more additives from the following groups, such as flavourings, sweeteners, colouring agents and preservatives. Oral administration forms contain the active ingredient together with non-toxic, pharmaceutically acceptable carrier materials which are suitable for the production of tablets, capsules, dragees etc., such as e.g. calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; starch, mannitol, methylcellulose, talc, highly dispersible silicic acids, high molecular fatty acids (such as stearic acid), groundnut oil, olive oil, parafen, miglyol, gelatine, agar-agar, magnesium stearate, beeswax, cetyl alcohol, lecithin, glycerol, animal and vegetable fats, solid high molecular polymers (such as polyethylene glycol). Tablets, capsules, dragees etc. can be provided with an appropriate coating, e.g. glyceryl mono-stearate or glyceryl distearate, in order to prevent undesired side effects in the gastrointestinal tract or to give a longer duration of action by the delayed absorption in the gastrointestinal tract As the injection medium there are preferably used sterile injectable aqueous or oily solutions or suspensions which contain the usual additives such as stabilizers and solubilizers. Such additives can be e.g. water, isotonic saline, 1,3-butanediol, fatty acids (such as oleic acid), mono- and diglycerides or miglyol. For rectal use there can be used all suitable non-irritating additives which are solid at normal temperatures and liquid at rectal temperatures, such as e.g. cocoa butter and polyethylene glycol. Pharmaceutically usual carrier media are used for application as aerosols. Creams, tinctures, gels, solutions or suspensions etc. with the pharmaceutically usual additives are used for external application. The dosage can depend n a variety of factors such as mode of administration, species, age and/or individual condition. The doses to be administered daily or at intervals lie at 1-1000 mg/individual, preferably at 10-250 mg/individual, and can be taken at one time or divided over several times.
- The compounds of formula (I) can also be applied locally to/in the bones (optionally with surgical intervention). The application directly to/in the bones (optionally with surgical intervention) can be effected locally or carrier-bonded either in solution or suspension, conveniently by infusion or injection. Carrier-bonded compounds of formula (I) can be administered, for example, as gels, pastes, solids or as a coating on implants.
- Biocompatible and preferably biodegradable materials are used as the carrier. Preferably, the materials themselves also induce wound healing or osteogenesis.
- For local application it is preferred that the compounds of formula (I) are imbedded in polymer gels or films in order to immobilize them and to apply these preparations directly on the site of the bone to be treated. Such polymer-based gels or films consist, for example, of glycerine, methylcellulose, hyaluronic acid, polyethylene oxides and/or poloxamers. Also suitable are collagen, gelatines and alginates and are described, for example, in WO 93/00050 and WO 93/20859. Further polymers are polylactic acid (PLA) and copolymers of lactic acid and glycolic acid (PLPG) (Hollinger el al., J. Biomed. Mater. Res. 17 71-82 (.1983)) as well as the bone derivative “Demineralized Bone matrix” (DBM) (Guterman et al. Kollagen Rel. Res. 8 419-4319 (1988). Also suitable are polymers as are used, for example, for the adsorption of TGFβ and which are described in EP-A 0 616 814 and EP-A-0 567 391 and synthetic bone matrices in accordance with WO 91/18558.
- Likewise suitable as carriers for the compounds of formula (I) are materials which are usually used for the implantation of bone substitutes or otherwise of therapeutically active substances. Such carriers are based, for example, on calcium sulphate, tricalcium phosphate, hydroxylapatite (sic) and its biodegradable derivatives and polyanhydrides. Apart from these biodegradable carriers there are also suitable carriers which are not biodegradable, but which are biocompatible. Such carriers are, for example, sintered hydroxylapatite, bioglass, aluminates or other ceramic materials (e.g. calcium aluminium phosphate). These materials are preferably used in combination with the biodegradable materials, such as especially polylactic acid, hydroxylapatite, collagen or tricalcium phosphate. Further non-degradable carriers are described, for example, in U.S. Pat. No. 4,164,560.
- It is especially preferred to use a carrier which liberates the compounds of formula (I) continuously at the target site. Especially suitable for this are e.g. “slow release pellets” from Innovative Research of America, Toledo, Ohio, USA. Pellets which release the compounds of formula (I) over several days, preferably up to 100 days with a daily dosage of 1-10 mg/kg per day, are especially preferred.
- Preferred in the scope of the present invention are, apart form the compounds named in the Examples and compounds derivable by a combination of all of the significances of the substituents set forth in the claims, the following derivatives as well as their physiologically compatible salts, esters, optically active forms, racemates, tautomers as well as derivatives which can be metabolized in vivo to compounds of general formula (I), as well as the use of these compounds for the production of medicaments, Preferred Compounds (PC):
- 1. [5-(9H-Fluoren-2-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 2. (4-Oxo-5-phenanthren-9-ylmethyl-2-thioxo-thiazolidin-3-yl)-acetic acid
- 3. [5-(3-Anthracen-9-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 4. 3-[5-(10-Methyl-anthracen-9-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 5. 3-[5-(5-Furan-2-yl-penta-2,4-dienylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 6. 2-(5-Benzylidene-4-oxo-2-thioxo-thiazolidin-3-yl)-succinic acid
- 7. 2-[5-(2-Methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 8. [4-Oxo-2-thioxo-5-(2,3,4-trimethoxy-benzyl)-thiazolidin-3-yl]-acetic acid
- 9. {5-[3-(2,4-Dimethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 10. 3-[4-Oxo-2-thioxo-5-(2,4,5-trimethoxy-benzylidene)-thiazolidin-3-yl]-propionic acid
- 11. 3-{4-Oxo-2-thioxo-5-[3-(2,4,6-trimethoxy-phenyl)-allylidene]-thiazolidin-3-yl}-propionic acid
- 12. 2-[5-(2,5-Dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 13. 2-[5-(2-Ethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 14. [5-(2-Hydroxy-3-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 15. {5-[3-(3-Ethoxy-2-hydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 16. 3-[5-(2,3-Dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 17. 3-{4-Oxo-2-thioxo-5-[3-(2,3,4-trihydroxy-phenyl)-allylidene]-thiazolidin-3-yl}propionic acid
- 18. 2-[5-(4-Diethylamino-2-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 19. 2-[5-(2-Hydroxy-4-methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 20. [5-(2-Hydroxy-5-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 21. {5-[3-(2,5-Dihydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 22. 3-[5-(2-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 23. 3-{5-[3-(4-Methoxy-2,3-dimethyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 24. 2-[4-Oxo-2-thioxo-5-(2,4,6-trimethyl-benzylidene)-thiazolidin-3-yl]-succinic acid
- 25. 2-[5-(2,5-Dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 26. {5-[3-(4-Methoxy-phenoxy)-benzyl]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 27. (5-{3-[3-(4-tert-Butyl-phenoxy)-phenyl]-allylidene}-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid
- 28. 3-[4-Oxo-2-thioxo-5-(3-#pl-tolyloxy-benzylidene)-thiazolidin-3-yl]-propionic acid
- 29. 3-{5-[3-(3-Methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 30. 2-[5-(3,4-Dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 31. 2-[4-Oxo-2-thioxo-5-(3,4,5-trimethoxy-benzylidene)-thiazolidin-3-yl]-pentanedicarboxylic acid
- 32. [5-(3,5-Dimethoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 33. {5-[3-(3-Benzyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 34. 3-[5-(3-Hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 35. 3-{5-[3-(3-Hydroxy-4-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 36. 2-[5-(3,4-Dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 37. 2-[5-(3-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 38. [5-(4-Dimethylamino-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 39. {5-[3-(4-Diethylamino-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 40. 3-[4-Oxo-5-(4-phenoxy-benzylidene)-2-thioxo-thiazolidin-3-yl]-propionic acid
- 41. 3-{5-[3-(4-Methoxy-phenyl)-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 42. 2-[5-(3-Benzyloxy-4-methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
-
- 44. [5-(4-Butoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 45. [5-(3-Naphthalen-1-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 46. 3-[5-(2-Methoxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 47. 3-{5-[3-(2-Hydroxy-naphthalen-1-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 48. 2-[5-(4-Methoxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 49. 2-(5-Naphthalen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-pentane-dicarboxylic acid
- 50. [5-(9-Ethyl-9H-carbazol-3-ylmethyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 51. {5-[3-(1H-Indol-3-yl)-allylidene]-4-oxo-2-thioxo-thiazoidin-3-yl}-acetic acid
- 52. 3-[5-(5-Methoxy-1H-indol-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 53. 3-[5-(3-Benzo [1,3]dioxol-5-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 54. 2-[5-(4-Hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 55. [5-(4-Hydroxy-3,5-dimethoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 56. {5-[3-(3-Ethoxy-4-hydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 57. 3-[5-(4-Hydroxy-3,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 58. 3-[5-(3-Biphenyl-4-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 59. 2-[5-[4-Isopropyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 60. [5-(4-Ethyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 61. [5-(4,4-Diphenyl-but-2-enylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 62. 3-[4-Oxo-5-[2-phenyl-propylidene)-2-thioxo-thiazolidin-3-yl]-propionic acid
- 63. 3-5-(4-Methyl-5-phenyl-penta-2,4-dienylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 64. 2-[5-[2-Hexyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 65. [4-Oxo-5-(5-phenyl-penta-2,4-dienylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid
- 66. 3-{5-[3-(2-Methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 67. 3-{5-[5-(4-Dimethylamino-phenyl)-penta-2,4-dienylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 68. [5-(3-Ethoxy-4-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 69. {5-[3-(4-Diethoxymethyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 70. 3-5-(4-Dimethylamino-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 71. 2-[5-(2,4-Dimethoxy-3-methyl-benzylidene-1-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 72 [4-Oxo-5-(4-styryl-benzylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid
- 73. 5-[4-(3-Dimethylamino-propoxy)-benzyl]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 74. {5-[3-(2,4-Dihydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 75. 3-[5-(2-Methyl-1H-indol-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 76. 3-{5-[3-(4-Hydroxy-3-methyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 77. 2-[5-(2-Hexyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 78. [4-Oxo-5-(4-propoxy-benzyl)-2-thioxo-thiazolidin-3-yl]-acetic acid
- 79. {4-Oxo-5-(3-(4-pentyloxy-phenyl)-allylidene]-2-thioxo-thiazolidin-3-yl}-acetic acid
- 80. 3-[5-[4-Octyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 81. 3-{5-[3-(5-Benzytoxy-1H-indol-3-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 82. 2-(5-Benzofuran-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-pentane-dicarboxylic acid
- 83. [4-Oxo-5-(2,3,4,5,6-pentamethyl-benzyl)-2-thioxo-thiazolidin-3-yl]-acetic acid
- 84. {5-[3-(2-Benzyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 85. 3-[4-Oxo-2-thioxo-5-(2,3,4-trimethoxy-6-methyl-benzylidene)-thiazolidin-3-yl]-propionic acid
- 86. 3-{5-[3-(3-Ethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 87. 2-[5-(3,4-Dihydroxy-5-methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 88. [5-(3,4-Dimethyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 89. {5-[3-(4-Ethoxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 90. 3-[5-(4-Hexyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 91. 3-{5-[3-(4-Heptydoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 92. 2-(5-Benzo[1,3]dioxol-4-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-pentanedicarboxylic acid
- 93. [4-Oxo-2-thioxo-5-(2,4,5-trimethyl-benzyl)-thiazolidin-3-yl]-acetic acid
- 94. {5-[3-(4-Decyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 95. 3-{5-[3-(4-tert-Butyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 96. {5-[3-(4-Amino-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 97. 3-[5-(2-tert-Butylsulphanyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 98. 3-{5-[3-(4-Butyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 99. 2-[5-(4-tert-Butoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 100. [4-Oxo-5-(4-propyl-benzyldene)-2-thioxo-thiazolidin-3-yl]-acetic acid
- 101. [5-(4-Hexyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 102. 5-[3-(4-Octyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid
- 103. 3-(5-(4-Dodecyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 104. 3-{4-Oxo-5-[3-(4pentyl-phenyl)-allylidene]-2-thioxo-thiazolidin-3-yl}-propionic acid
- 105. 2-[5-(3-Amino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 106. [3-(7-Methyl-1H-indol-3-ylmethyl)-4-oxo-2-thioxo-lLiazolidin-3-yl]-acetic acid
- 107. 3-[4-Oxo-2-thioxo-5-(2-p-tolyl-ethylidene)-thiazolidin-3-yl]-propionic acid
- 108. 3-{5-[3-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 109. [5-(4-Hydroxy-2-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 110. {5-[3-(2,2-Dimethyl-chroman-6-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 111. 3-[5-(4-Isopropoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 112. 2-[5-(4-Methyl-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 113. {5-[3-(2,3-Dihydro-benzofuran-5-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 114. 3-(4-Oxo-5-quinolin-2-ylmethylene-2-thioxo-thiazolidin-3-yl)-propionic acid
- 113. 3-{5-[5-(4-Diethylamino-phenyl)-penta-2,4-dienylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 116. 2-[5-(4-Isobutyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 117. [5-(6-Methoxy-naphthalen-2-ylmethyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 118. {5-[3-(3,5-Dimethyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 119. 3-[5-(1-Hydroxy-naphthalen-2-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 120. [5-(4-Octadecyloxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 121. {5-[3-(4-Diphenylamino-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 122. 3-[4-Oxo-2-thioxo-5-(3,4,5-trihydroxy-benzylidene)-thiazolidin-3-yl]-propionic acid
- 123. 3-{5-[3-(4-Dimethylamino-2-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 124. {5-[2-(2-Hydroxy-ethoxy)-benzyl]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 125. (5-{3-[4-(2-Hydroxy-ethoxy)-phenyl]-allylidene}-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid
- 126. 3-[5-(2-Benzyloxy-ethylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 127. 3-{5-[3-(4-tert-Butoxycarbonyloxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 128. 2-[5-(2,4-Diethoxy-3-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 129. [5-(2-Benzyloxy-3-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 130. {5-[3-(4-Methanesulphonyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 131. 3-[5-(2-Hydroxy-5-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 132. (4-Oxo-5-thiophen-2-ylmethyl-2-thioxo-thiazolidin-3-yl)-acetic acid
- 133. [5-(5-Naphthalen-2-yl-penta-2,4-dienylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 134. 3-[4-Oxo-5-(3-thiophen-2-yl-allylidene)-2-thioxo-thiazolidin-3-yl]-propionic acid
- 135. 3-{5-[3-(2-[1,3]Dioxolan-2-yl-6-fluoro-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 136. 2-[5-(3-tert-Butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 137. [5-(4-Benzyl-benzyl)-4-oxo-2-thioxo-thiazohidin-3-yl]-acetic acid
- 138. {5-[5,9-Dimethyl-11-(2,6,6-trimethyl-cyclohex-1-enyl)-undeca-2,4,6,8,10-pentaenylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 139. 3-[4-Oxo-5-(1H-pyrrol-2-ylmethylene)-2-thioxo-thiazolidin-3-yl]-propionic acid
- 140. 3-[5-[3-Furan-2-yl-allylidene)-4-oxo-2-thioxo-thiazoldin-3-yl]-propionic acid
- 141. 2-{5-[3-(5,6-Diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-pentanedicarboxylic acid
- 142. (4-Oxo-5-pyridin-2-ylmethylene-2-thioxo-thiazolidin-3-yl)-acetic acid
- 143. [5-(1-Methyl-1H-pyrrol-3-ylmethyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 144. {5-[3-(2-Hydroxy-4,6-dimethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 145. 3-[5-[4-Benzyloxy-2-hydroxy-benzylidene)-4-oxo-2-tioxo-thiazolidin-3-yl]-propiorlic acid
- 146. 3-{5-[3-(5-Benzyloxy-2-hydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 147. 2-{5-[4-(Benzo[1,3]dioxol-5-ylmethoxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-pentanedicarboxylic acid
- 148. [5-(4-Benzyloxy-3,5-dihydroxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 149. {5-[3-(2,5-Bis-benzyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}acetic acid
- 150. 3-[5-(4-Benzyloxy-3,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 151. 3-[5-(3-Cyclohexyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 152. 2-{5-[3-Methyl-5-(2,6,6-trimethyl-cydohex-1-enyl)-penta-2,4-dienylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-pentanedicarboxylic acid
- 153. [5-(3,4-Diethoxy-2,5-dimethyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 154. {5-[5-(3,4-Diethoxy-2,3-dimethyl-phenyl)-penta-2,4-dienylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 155. [5-(2-Carboxymethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 156. 2-{3-[3-(2-Carboxy-ethyl)-4-oxo-2-thioxo-thiazolidin-5-yliden]-propenyl}-benzoic acid
- 157. 2-[5-(4-Acetoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 158. Methyl 4-(3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-benzoate
- 159. 4-[3-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-yliden)-propenyl]-benzoic acid
- 160. 3-{4-[3-(2-Carboxy-ethyl)-4-oxo-2-thioxo-thiazolidn-5-ylidenmethyl]-phenyl}-acrylic acid
- 161. 3-{4-Oxo-5-[3-(4-oxo-4H-chromen-3-yl)-allylidene]-2-thioxo-thiazolidin-3-yl}-propionic acid
- 162. 2-[5-(4-Acetoxy-3,5-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 163. 3-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-benzoic acid
- 164. 4-[3-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-yliden)-propenyl]-phenyl propionate
- 165. 3-[5-(5,7-Dimethyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid
- 166. 3-{5-[3-(2-Ethoxycarbonylmethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 167. 2-5-(8-Carboxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 168. [5-(3,4-Diacetoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid
- 169. {5-[3-(2-Amino-4-oxo-4H-chromen-3-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 170. 3-[5-(2-Amino-6,7-dimethyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl -propionic acid
- 171. 3-{5-[3-(6-Ethyl-4-oxo-4H-cchromen-3-yl)-allylidenej -4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 172. 2-[5-(6,8-Dimethyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedicarboxylic acid
- 173. Methyl 2-(3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-benzoate
- 174. Methyl 3-[3-[3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-yliden)-propenyl]-1H-indole-6-carboxylate
- 175. 3-{5-[3-(4-Acetoxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 176. 3-[4-Oxo-5-(3-phenyl-but-2-enylidene)-2-thioxo-thiazolidin-3-yl]-propionic acid
- 177. 2-(4-Oxo-2-thioxo-5-(1-#pl-tolyl-ethylidene)-thiazolidin-3-yl]-pentane-dicarboxylic acid
- 178. {5-(1-(4-Methoxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 179. {5-[1-(3,4-Dichloro-phenyl)-ethyl]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
- 180. [4-Oxo-5-(3-thiophen-2-yl-but-2-enylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid
- 181. 3-[4-Oxo-5-(11-oxo-6,11-dihydro-dibenzo[b,e]oxepin-3-ylmethylene)-2-thioxo-thiazolidin-3-yl]-propionic acid
- 182. 3-{5-[3-(3,5-Dihydroxy-phenyl)-but-2-enylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
- 183. 2-[5-(4-Hydroxy-3-methobenzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 184. 2-[5-(4-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 185. 2-(4-Oxo-5-phenthylidene-2-thioxo-thiazolidin-3-yl)-succinic acid
- 186. 2-5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 187. 2-[4-Oxo-5-(4-styryl-benzylidene)-2-thioxo-thiazolidin-3-yl]-succinic acid
- 188. 2-[5-(4-Allyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 189. 2-[4-Oxo-5-(4-pyrrolidin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]-succinic acid
- 190. 2-(5-(3,5-Dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 191. 2-{5-[3-(4-Methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-succinic acid
- 192. 2-[4-Oxo-5-(4-propyl-benzylidene)-2-thioxo-thiazolidin-3-yl]-succinic acid
- 193. 2-[5-(2-Ethoxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-y]-succinic acid
- 194. 2-[5-(3-Furan-2-yl-2-methyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 195. 2-{5-[3-(4-Hydroxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-succinic acid
- 196. 2-{5-[3-(4-tert-Butyl-phenyl)-2-methyl-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-succinic acid
- 197. 2-{5-[3-(2-Hydroxy-ethoxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-succinic acid
- 198. 2-{5-[3-(4-Hydroxy-3,5-dimethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-succinic acid
- 199. 2-[5-(3-Benzo[b]thiophen-2-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 200. 2-[5-(2,4-Bis-benzyloxy-benzylidene)-4-oxo-2-thioxo-tniazolidin-3-yl]-succinic acid
- 201. 2-(4-Oxo-5-pyridin-2-ylmethylene-2-thioxo-thiazolidin-3-yl-succinic acid
- 202. 2-[5-(4-Benzyloxy-3,5-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 203. 2-[5-(3-Biphenyl-4-yl-allylidene)-4-oxo-2-thioxo-thiazoiidin-3-yl]-succinic acid
- 204. 2-[5-(3-Carboxy-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 205. 2-[5-(4-Carboxymethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 206. 2-[5-(6-Methyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 207. 2-[5-(6-Isopropyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid
- 208. 2-{5-[1-(4-Methoxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-succinic acid
- The following Examples show some process variants which can be used for the synthesis of the compounds in accordance with the invention. However, they are not intended to be a limitation of the object of the invention. The structure of the compounds was proven by1H- and, where necessary, by 13C-NMR spectroscopy. The purity of the substances was determined by C, H, N, P analysis as well as by thin-layer chromatography.
- General Process A
- 5 mmol of aldehyde of the formula R—CO, wherein R has the significance given above, and 5 mmol of 4-oxo-2-thioxo-thiazolidin-3-ylcarboxylic acid derivative are heated at reflux for 10 hours together with 15 mmol of sodium acetate and 15 ml of glacial acetic acid. After cooling, the mixture is poured into H2O. The precipitate is filtered off under suction, rinsed with H2O and dried. For purification, it is chromatographed over silica gel with ethyl acetate/heptane (2:1).
- The preparation of 2-(4-oxo-2-thioxo-thiazolidin-3-yl)-glutaric acid and 2-(4-oxo-2-thioxo-thiazolidin-3-yl)-succinic acid is effected according to Chem. Heterocycl. Compd. EN 3 528-30 (1967).
- 2-(5-Benzo[b]thiophen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-succinic acid (1) Yellow crystals; m.p. 240° C. (dec.)
- 2-(5-Benzo [b]thiophen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-pentanedioic acid (2) Yellow crystals; m.p. 220-1° C.
- 2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-phenyl-propionic acid (3) Yellow crystals; m.p. 160° C. (dec.)
- 2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-(1H-indol-3-yl)-propionic acid (4) Orange crystals; m.p. 140° C. (dec.)
- [5-(5-Acetylamino-benzo[b]thiophen-2-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (5) Yellow crystals; m.p. >240° C.
- 5-[3-(4-Methoxy-2,5-dimethyl-phenyl)-allyliden]-4-oxo-2-thioxo-thiazoiidin-3-yl-acetic acid (6) Red crystals; m.p. >240° C.
- 5-[3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (7) Yellow crystals; m.p. >240° C.
- [5-(2,3-Dihydro-benzofuran-5-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (8) Yellow crystals; m.p. 246-7° C.
- (4-Oxo-5-thiophen-2-ylmethylene-2-thioxo-thiazolidin-3-yl)-acetic acid (9) Yellow crystals; m.p. 237-9° C.
- (5-Benzo [b]thiophen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid (10) Yellow crystals; m.p. 292-4° C.
- [5-(3-Naphthalen-2-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (11) Orange crystals; 275-7° C.
- [5-(4-Methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (12) Yellow crystals; m.p. 244-6° C.
- [5-(5-Benzo [b]thiophen-2-yl-penta-2,4-dienylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (13) Red crystals; m.p. >240° C.
- [5-(4-Hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (14) Yellow crystals; m.p. 230-2° C.
- [5-(4-Methoxy-2,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (15) Yellow crystals; m.p. 240° C.
- [5-(3-Benzo [b]thiophen-2-yl-allylidene)-4-oxo-2-thioxo-thiazoldin-3-yl]-acetic acid (16) Orange crystals; m.p. >240° C.
- [5-(4-Methoxy-3-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (17) Yellow crystals; m.p. 235-6° C.
- 2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pentanedioic acid (18) Yellow crystals; m.p. 130° C. (dec.)
- [5-(4-Benzyloxy-35-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (19) M.p. 128-30° C.
- [5-(3,4-Bis-benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (20) Yellow crystals; m.p. 187-8° C.
- [5-(3-Biphenyl-yl-allylidene)-4-oxo-2-thioxo-Lhiazolidin-3-yl]-acetic acid (21) Orange crystals; m.p. 130° C. (dec.)
- 5-[1-Methyl-3-[2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (22) Brown crystals; m.p. 100° C. (dec.)
- [5-(3-tert-Butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (23) Yellow crystals; m.p. >240° C.
- 2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-succinic acid (24) Brown crystals; m.p. 240° C. (dec.)
- [5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (25) Orange crystals; m.p. 120-1° C.
- [5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (26) Yellow crystals; m.p. 205-6° C.
- 5-[1-[3,5-Dihydroxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid Yellow crystals; m.p. 184-8° C.
- 5-[-(4-Carboxymethoxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (28) Yellow crystals; m.p. 111-20° C. (dec.)
- (4-Oxo-2-thioxo-5-(2,3,4-trihydroxy-benzylidene)-thiazolidin-3-yl)-acetic acid (29) Ochre-coloured crystals; m.p. 263° C. (dec.)
- [5-(2-Hydroxy-4,6-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (30) Pale brown crystals; m.p. 194° C. (dec.)
- [5-(3-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (31) Yellow crystals; m.p. 178-81° C.
- 3-[5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid (32) Yellow crystals; m.p. 188-91° C.
- 2-[5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid (33) Yellow crystals; m.p. 125-8° C.
- [5-(5-Benzyloxy-2-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (34) Orange crystals; m.p. 130-3° C.
- 5-[4-(4-Methoxy-benzyloxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (35) Yellow crystals; m.p. 172-3° C.
- 5-[4-(Benzo[1,3]dioxol-5-ylmethoxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (36) Yellow crystals; m.p. 206-7° C.
- 5-[4-Oxo-2-thioxo-5-(3,4,5-trihydroxy-benzylidene)-thiazolidin-3-yl]-pentanecarboxylic acid (37) m.p. 212-4° C.
- 5-[4-(3-Methoxy-benzyloxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (38) Yellow crystals; m.p. 191-3° C.
- [5-(4-Hydroxy-3,5dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (39) Orange crystals; m.p. 277-9° C.
- [5-(4-Benzyloxy-3,3-dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (40) M.p. 178-80° C.
- [5-(2,5-Bisbenzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (41) Yellow crystals; m.p. 196-8° C.
- [4-Oxo-2-thioxo-5-(3,4,5-triacetoxy-benzylidene)-thiazolidin-3-yl]-acetic acid (42) Orange crystals; m.p. 200° C. (dec.)
- 5-(3-(5,6-Diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxa-2-thioxo-thiazolidin-3-yl-acetic acid (43) Red crystals; m.p. 252-30C.
- (5-Cyclohex-3-enybnethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid (44) Beige crystals; m.p. 180-2° C.
- [4-Oxo-5-(3-phenyl-propylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid (45) Orange crystals; m.p. 108-11° C.
- 5-(3-Methyl-5-(2,6,6trimethyl-cyclohex-1-enyl)-penta-2,4-dienyliden]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (46) Orange crystals; m.p. 153-5° C.
- 5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-3-methyl-2-thioxo-thiazolidin-4-one (47) Yellow crystals; m.p. >240° C.
- Methyl [5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetate (48) Yellow crystals; m.p. 165-70° C.
- 2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-N,N-diethyl-acetamide (49) Yellow crystals; m.p. 223-5° C.
- Methyl 5-[3-(5,6-diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetate (50) Violet crystals; m.p. 211-5° C.
- 2-5-[3-(5,6-Diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-N,N-diethyl-acetamide (51) Red crystals; m.p. 210-2° C.
- Benzyl 4-(3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylidenmethyl)-piperidine-1-carboxylate (52) Yellow crystals; m.p. 114-5° C.
- 5-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (53) Black (sic) crystals; m.p. 144° C. (dec.)
- [5-(3,4-Dihydroxy-2,3-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (54) Yellow crystals; m.p. >240° C.
- [5-(3,4-Diethoxy-2,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (55) Ochre coloured crystals; m.p. 185-90° C.
- 5-[3-(3,4-Diethoxy-2,5-dimethyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (56) Green crystals; m.p. 210° C. (dec.)
- 5-[5-Methyl-7-[2,6,6-triethyl-cyclohex-1-enyl)-hepta-2,4,6-trienyliden]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (57) Black crystals; m.p. 192-5° C.
- 3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-propionic acid (58) Yellow crystals; m.p. 174-6° C.
- 3-(4-Oxo-2-thioxo-5-(2,6,6-trimetyl-cyclohex-1-enylmethylene)-thiazolidin-3-yl]-propionic acid (59) Yellow-orange crystals; m.p. 166-8° C.
- 3-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid (60) Yellow crystals; m.p. 218-9° C.
- 3-(5-Naphthalen-1-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-propionic acid (61) Orange crystals; m.p. 159-61° C.
- 3-[5-(3-Benzo[b]thiophen-2-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid (62) Orange crystals; m.p. 246-8° C.
- [5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (63) Orange crystals; m.p. 186-8° C.
- [4-Oxo-5-(4-pentyl-benzylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid (64) Yellow crystals; m.p. 160-2° C.
- [5-(3-Methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (65) Yellow crystals; m.p. 193-6° C.
- [4-Oxo-2-thioxo-5-(2,4,5-trirmethyl-benzylidene)-thiazolidin-3-yl]-acetic acid (66) Yellow crystals; m.p. 234-6° C.
- [5-(2-Hexyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (67) Yellow crystals; m.p. 148-50° C.
- [5-(4-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (68) Yellow crystals; m.p. 234-6° C.
- [5-(4-Methoxy-2,3-dinethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (69) Yellow crystals; m.p. 215-7° C.
- [5-(4-Hydroxy-3,5-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (70) Orange crystals; m.p. 238-40° C.
- 5-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylidenmethyl)-2-hydroxy-benzoic acid (71) Yellow crystals; m.p. >260° C.
- 3-5-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-propionic acid (72) Orange crystals; m.p. 160-1° C.
- [5-(1,4-Dihydroxy-10-methoxy-5,8-dimethyl-3,7-dioxo-1,3-dihydro-7H-benzo[e]furo[3′,4′:3,4]benzo[b][1,4]dioxepin-11-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (73) Dark green crystals; m.p. >260° C.
- [5-(2-Methyl-1H-indol-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (74) Brown crystals; m.p. 268-70° C.
- [5-(3,4-Diacetoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid (75) Yellow crystals; m.p. 193-53° C.
- Compounds of general formula (I) were investigated in a suitable assay for the capability of stimulating cyclic adenylate cyclase.
TABLE I % cAMP Example No. Name (Test conc. 50 μM) 3 2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo- 8 2-thioxo-thiazolidin-3-yl]-3-phenyl-propionic acid 13 [5-(5-Benzo[b]thiophen-2-yl-penta-2,4-dienylidene)-4- 10 oxo-2-thioxo-thiazolidin-3-yl]-acetic acid 16 [5-(3-Benzo[b]thiophen-2-yl-allylidene)-4-oxo-2- 8 thioxo-thiazolidin-3-yl]-acetic acid 22 5-[1-Methyl-3-(2,6,6-trimethyl-cydohex-1-enyl)- 10 allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid 23 [5-(3-tert-Butyl-4-hydroxy-benzylidene)-4-oxo-2- 8 thioxo-thiazolidin-3-yl]-acetic acid 25 [5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2- 40 thioxo-thiazolidin-3-yl]-acetic acid 46 5-[3-Methyl-5-(2,6,6-trimethyl-cyclohex-1-enyl)-penta- 30 2,4-dienylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid 59 3-[4-Oxo-2-thioxo-5-(2,6,6-trimethyl-cyclohex-1- 15 enylmethylene)-thiazolidin-3-yl]-propionic acid 60 3-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo- 20 2-thioxo-thiazolidin-3-yl]-propionic acid 72 3-5-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)- 15 allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-propionic acid
Claims (3)
1. Use of compounds of general formula (I)
in which
m signifies a number between 0-8,
q signifies a number between 0-8
a signifies a number between 0-4
A signifies a single or double bond
R1, R2 signify hydrogen or lower alkyl, whereby R1 and R2 can be the same or different and, when m signifies 2-8, R1 and R2 in the group CR1═CR2 can have various significances within the following sequence
R3 signifies hydrogen or lower alkyl
X signifies hydrogen or —(CH2)b—COR4 with b=0-4
Y signifies hydroxyl, —COR4, phenyl or indolyl residue
R4 signifies hydroxyl, lower alkoxy or the NR1R2 residue, whereby R1 and R2 can be the same or different
W signifies an optionally mono- or polysubstituted saturated or unsaturated mono-, bi- or tricycle which can contain one or more hetero atoms,
for the preparation of medicaments for the treatment and prevention of metabolic bone disorders,
2. Compounds of general formula (I)
in which
m signifies a number between 0-8,
q signifies a number between 0-8
a signifies a number between 0-4
A signifies a single or double bond
R1, R2 signify hydrogen or lower alkyl, whereby R1 and R2 can be the same or different and, when m signifies 2-8, R1 and R2 in the group CR1═CR2 can have various significances within the following sequence
R3 signifies hydrogen or lower alkyl
X signifies hydrogen or —(CH2)b—COR4 with b=0-4
Y signifies hydroxyl, —COR4, phenyl or indolyl residue
R4 signifies hydroxyl, lower alkoxy or the NR1R2 residue, whereby R1 and R2 can be the same or different
W signifies an optionally mono- or polysubstituted saturated or unsaturated mono-, bi- or tricycle which can contain one or more hetero atoms,
whereas W is not phenyl or indolyl, if m and g are both 0, R3, is hydrogen and A is a double bond,
as well as their physiologically compatible salts, esters, optically active forms, racemates, tautomers, as well as derivatives which can be metabolized in vivo to compounds of general formula (I)
3. Medicament containing at least one compound of general formula (I) according to claim 2 in admixture with usual pharmaceutical adjuvents and carrier material
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/199,057 US20030032813A1 (en) | 1998-09-30 | 2002-07-22 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98118493 | 1998-09-30 | ||
EP98118493.0 | 1998-09-30 | ||
EPPCT/EP99/07248 | 1999-09-30 | ||
US09/787,917 US6673816B1 (en) | 1998-09-30 | 1999-09-30 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
PCT/EP1999/007248 WO2000018747A1 (en) | 1998-09-30 | 1999-09-30 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
US10/199,057 US20030032813A1 (en) | 1998-09-30 | 2002-07-22 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/787,917 Division US6673816B1 (en) | 1998-09-30 | 1999-09-30 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030032813A1 true US20030032813A1 (en) | 2003-02-13 |
Family
ID=8232720
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/787,917 Expired - Fee Related US6673816B1 (en) | 1998-09-30 | 1999-09-30 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
US10/199,057 Abandoned US20030032813A1 (en) | 1998-09-30 | 2002-07-22 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/787,917 Expired - Fee Related US6673816B1 (en) | 1998-09-30 | 1999-09-30 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
Country Status (5)
Country | Link |
---|---|
US (2) | US6673816B1 (en) |
EP (1) | EP1117655A1 (en) |
JP (1) | JP2002525362A (en) |
AU (1) | AU6330799A (en) |
WO (1) | WO2000018747A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5311800A (en) * | 1999-06-10 | 2001-01-02 | Warner-Lambert Company | Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
US6506755B2 (en) * | 2000-02-03 | 2003-01-14 | Hoffmann-La Roche Inc. | Thiazolidinecarboxyl acids |
GB0021421D0 (en) * | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
GB0021419D0 (en) * | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
GB2386892A (en) * | 2002-03-28 | 2003-10-01 | Pantherix Ltd | Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
NZ563846A (en) * | 2005-06-03 | 2010-03-26 | Egalet As | A drug delivery system for delivering active substances dispersed in a dispersion medium |
WO2007098010A2 (en) * | 2006-02-17 | 2007-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Improved low molecular weight myc-max inhibitors |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
CN106045987B (en) * | 2016-06-21 | 2019-04-23 | 广东工业大学 | One kind having multi-functional near-infrared fluorescent magnetic nanoparticle and its preparation and application |
EP3404022B1 (en) * | 2017-05-19 | 2020-10-07 | Paris Sciences et Lettres - Quartier Latin | Membrane-impermeant fluorogenic chromophores |
RU2768171C2 (en) * | 2019-07-11 | 2022-03-23 | Общество С Ограниченной Ответственностью "Научно-Исследовательский Центр "Парк Активных Молекул" (Ооо "Ниц Пам") | Use of rhodanine derivative 3-(2-phenylethyl)-2-thioxo-1,3 thiazolidin-4-one for correction of metabolic disorders |
RU2768456C2 (en) * | 2019-07-11 | 2022-03-24 | Общество С Ограниченной Ответственностью "Научно-Исследовательский Центр "Парк Активных Молекул" (Ооо "Ниц Пам") | Use of rhodanine derivative 3-(2-phenylethyl)-2-thioxo-1,3 thiazolidin-4-one for normalization of metabolism, increase of non-specific resistance, growth and development of animals |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3704296A (en) * | 1967-06-06 | 1972-11-28 | Establissements Clin Byla | Substituted thiazolidine-4-ones |
US4777259A (en) * | 1985-07-10 | 1988-10-11 | Taiho Pharmaceutical Company Limited | Rhodanine derivatives and process for preparing the same |
US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
US5143927A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 3-(thiazolidone, oxazolidinone, imidazolidinone)-indoles as antiinflammatory agents |
US5747517A (en) * | 1994-03-16 | 1998-05-05 | Eli Lilly And Company | Benzylidene rhodanines |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5728074A (en) | 1980-07-28 | 1982-02-15 | Ono Pharmaceut Co Ltd | Rhodanine derivative, its preparation, and inhibitor for aldose reducing enzyme consisting essentially of it |
JPS5740478A (en) * | 1980-08-22 | 1982-03-06 | Ono Pharmaceut Co Ltd | Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative |
DK4487A (en) * | 1986-01-07 | 1987-07-08 | Yamanouchi Pharma Co Ltd | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE |
AU1558288A (en) * | 1987-05-11 | 1988-11-17 | Kaken Pharmaceutical Co., Ltd. | Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same |
IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
DK0391644T3 (en) | 1989-04-07 | 1996-07-15 | Lilly Co Eli | Aryl-substituted rhodanine derivatives |
IL95880A (en) * | 1989-10-13 | 1995-12-31 | Pfizer | Use of 3-substituted-2-oxindole derivatives for the preparation of a pharmaceutical preparation for inhibiting interleukin-1 biosynthesis |
ZA9010041B (en) | 1989-12-21 | 1992-08-26 | Lilly Co Eli | Compounds for treating inflammatory bowel disease |
IL106877A (en) * | 1992-09-10 | 1998-03-10 | Lilly Co Eli | Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease |
DE4318550A1 (en) * | 1993-06-04 | 1994-12-08 | Boehringer Mannheim Gmbh | Arylidene-4-oxo-2-thioxo-3-thiazolidinecarboxylic acids, process for their preparation and pharmaceutical compositions containing them |
US5476865A (en) * | 1994-07-06 | 1995-12-19 | Eli Lilly And Company | Methods of inhibiting bone loss |
IL117208A0 (en) | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
GB9614402D0 (en) * | 1996-07-09 | 1996-09-04 | Smithkline Beecham Spa | Novel compounds |
-
1999
- 1999-09-30 EP EP99950575A patent/EP1117655A1/en not_active Withdrawn
- 1999-09-30 WO PCT/EP1999/007248 patent/WO2000018747A1/en not_active Application Discontinuation
- 1999-09-30 US US09/787,917 patent/US6673816B1/en not_active Expired - Fee Related
- 1999-09-30 AU AU63307/99A patent/AU6330799A/en not_active Abandoned
- 1999-09-30 JP JP2000572207A patent/JP2002525362A/en active Pending
-
2002
- 2002-07-22 US US10/199,057 patent/US20030032813A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3704296A (en) * | 1967-06-06 | 1972-11-28 | Establissements Clin Byla | Substituted thiazolidine-4-ones |
US4777259A (en) * | 1985-07-10 | 1988-10-11 | Taiho Pharmaceutical Company Limited | Rhodanine derivatives and process for preparing the same |
US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
US5143927A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 3-(thiazolidone, oxazolidinone, imidazolidinone)-indoles as antiinflammatory agents |
US5747517A (en) * | 1994-03-16 | 1998-05-05 | Eli Lilly And Company | Benzylidene rhodanines |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056862B2 (en) | 2011-05-10 | 2015-06-16 | National University Corporation Kobe University | Thioxothiazolidine derivative having Ras function inhibitory effect |
Also Published As
Publication number | Publication date |
---|---|
AU6330799A (en) | 2000-04-17 |
WO2000018747A1 (en) | 2000-04-06 |
EP1117655A1 (en) | 2001-07-25 |
JP2002525362A (en) | 2002-08-13 |
US6673816B1 (en) | 2004-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6673816B1 (en) | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | |
US4438141A (en) | Thiazolidine derivatives | |
AU626863B2 (en) | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents | |
US5208250A (en) | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents | |
DE2324443A1 (en) | BENZOXAZOLE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURING | |
HRP20020177A2 (en) | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments | |
BRPI0616217A2 (en) | thiazolinones and oxazolinones and their uses as ptp1b inhibitors | |
Toja et al. | 3-Alkyl-2-aryl-3H-naphth [1, 2-d] imidazoles, a novel class of nonacidic antiinflammatory agents | |
BRPI0211844B1 (en) | phenoxy acetic acid compound or one of its pharmaceutically acceptable salts, and, pharmaceutical composition | |
US5478853A (en) | Thazolidinedione compounds | |
TW400330B (en) | Novel thiazolidine-2, 4-dione, substitute, the manufacture method and the pharmaceutical compositions therefof | |
JPS6242977A (en) | Di-t-butylphenol compound | |
WO2000018748A1 (en) | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders | |
US5110831A (en) | Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors | |
US3962452A (en) | Benzoxazole derivatives as therapeutics | |
US4560686A (en) | Method for treating circulatory diseases by using (2-lower alkoxyphenyl)piperazine derivatives | |
DE60130031T2 (en) | DIHYDRONAPHTHALIN DERIVATIVES COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS AS AN ACTIVE SUBSTANCE | |
WO2000018746A1 (en) | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders | |
AU763111B2 (en) | Polycyclic 2-amino-thiazole systems, method for the production thereof and medicament containing said compounds | |
US5506245A (en) | Thiazolidinedione compounds | |
DE19619819A1 (en) | New thiazolidinediones, process for their preparation and medicaments containing them | |
HRP20020178A2 (en) | Use of bis-sulphonamides for producing medicaments used for preventing or treating hyperlipidaemia | |
US4285943A (en) | Novel pharmaceutical compositions incorporating an aryltrifluoroethanol | |
US3655661A (en) | Benzothiadiazole compounds | |
US4029790A (en) | 1-Benzoyl-2 or 4 [2-(4-phenyl-piperazino)-ethyl]-piperidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |